Cargando…
Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
Myotonic Dystrophies type 1 (DM1) and type 2 (DM2) are complex multisystem diseases without disease-based therapies. These disorders are caused by the expansions of unstable CTG (DM1) and CCTG (DM2) repeats outside of the coding regions of the disease genes: DMPK in DM1 and CNBP in DM2. Multiple cli...
Autor principal: | Timchenko, Lubov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499601/ https://www.ncbi.nlm.nih.gov/pubmed/36142405 http://dx.doi.org/10.3390/ijms231810491 |
Ejemplares similares
-
Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1
por: Timchenko, Lubov
Publicado: (2019) -
Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
por: Timchenko, Lubov
Publicado: (2022) -
GSK3β is a new therapeutic target for myotonic dystrophy type 1
por: Wei, Christina, et al.
Publicado: (2013) -
Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
por: Schoser, Benedikt, et al.
Publicado: (2010) -
Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy
por: Lutz, Maggie, et al.
Publicado: (2023)